Type I interferons in metabolic syndrome.

Abstract

The global medical burden of metabolic disorders is on the rise, despite active interventions being developed targeting the majorly identified patho-mechanistic nodes. Several studies in the past decade or so revealed the critical role played by type 1 interferons, the family of pleiotropic cytokines, in different contexts of metabolic disorders. Important translational insights are already provided by meticulous studies in different preclinical models representing various discreet components of metabolic syndrome, with validation in human patients suffering from metabolic disorders. So successful translation of the mechanistic, preclinical, and clinical insights gathered in this domain can lead to novel clinically relevant therapeutics.